Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Subcutaneous Emphysema”

137 trials

Showing 20 of 137 results

Large-scale testing (Phase 3)Looking for participantsNCT06165341
What this trial is testing

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Who this might be right for
Alpha1-Antitrypsin Deficiency
Takeda 50
Large-scale testing (Phase 3)Active Not RecruitingNCT01983241
What this trial is testing

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

Who this might be right for
Pulmonary Emphysema in Alpha-1 PI Deficiency
Grifols Therapeutics LLC 345
Not applicableLooking for participantsNCT05178277
What this trial is testing

Czech AATD Registry

Who this might be right for
Alpha-1-antitrypsin Deficiency
Thomayer University Hospital 300
Testing effectiveness (Phase 2)WithdrawnNCT01183455
What this trial is testing

A Research Trial of Aralast NP in New Onset Diabetes (RETAIN) - Part II

Who this might be right for
Diabetes Mellitus, Type 1
National Institute of Allergy and Infectious Diseases (NIAID)
Not applicableEnrolling By InvitationNCT06892236
What this trial is testing

Preparation of IPSC for Cell Gene Editing for the Treatment of AATD

Who this might be right for
Alpha1-antitrypsin Deficiency
Fondazione IRCCS Policlinico San Matteo di Pavia 3
Testing effectiveness (Phase 2)Study completedNCT03945292
What this trial is testing

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

Who this might be right for
Alpha 1-Antitrypsin Deficiency
Arrowhead Pharmaceuticals 40
Early research (Phase 1)Study completedNCT05727800
What this trial is testing

A Phase 1, First-in-human Study of VX-668

Who this might be right for
Alpha-1 Antitrypsin Deficiency
Vertex Pharmaceuticals Incorporated 114
Early research (Phase 1)Study completedNCT00430768
What this trial is testing

Experimental Gene Transfer Procedure to Treat Alpha 1-Antitrypsin (AAT) Deficiency

Who this might be right for
Alpha 1-Antitrypsin Deficiency
University of Massachusetts, Worcester 9
Testing effectiveness (Phase 2)Study completedNCT02947087
What this trial is testing

Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis

Who this might be right for
Chronic Pancreatitis
Medical University of South Carolina 48
Not applicableStudy completedNCT04840953
What this trial is testing

Negative Pressure Therapy, Minimally Invasive and Accessible Technique in the Treatment of Massive Subcutaneous Emphysema in COVID-19 or Non Infected Critical Patients

Who this might be right for
Subcutaneous EmphysemaCovid19
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana 2
Large-scale testing (Phase 3)Active Not RecruitingNCT05899673
What this trial is testing

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

Who this might be right for
Alpha1-Antitrypsin Deficiency
Takeda 31
Not applicableStudy completedNCT00499941
What this trial is testing

Alpha-1 Foundation Research Registry

Who this might be right for
Alpha 1-Antitrypsin Deficiency
Medical University of South Carolina 6,655
Testing effectiveness (Phase 2)WithdrawnNCT03385395
What this trial is testing

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

Who this might be right for
Alpha 1-Antitrypsin Deficiency
Octapharma
Post-approval studies (Phase 4)Study completedNCT00396006
What this trial is testing

Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhibitor)

Who this might be right for
Alpha 1-Antitrypsin Deficiency
Baxalta now part of Shire 21
Testing effectiveness (Phase 2)Looking for participantsNCT06389877
What this trial is testing

Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)

Who this might be right for
Alpha 1-Antitrypsin Deficiency
Beam Therapeutics Inc. 106
Not applicableStudy completedNCT04262284
What this trial is testing

Respreeza® Self-administration and Learning Program (AmAREtTI Study)

Who this might be right for
Alpha-1 Antitrypsin Deficiency
CSL Behring 15
Post-approval studies (Phase 4)Study completedNCT01651351
What this trial is testing

GLASSIA Infusion Rate Study

Who this might be right for
Alpha1-antitrypsin DeficiencyHealthy Volunteers
Baxalta now part of Shire 30
Not applicableUnknownNCT04966221
What this trial is testing

Functional and Structural Lung Imaging in Chronic Obstructive Pulmonary Disease

Who this might be right for
Chronic Obstructive Pulmonary DiseaseAlpha 1-Antitrypsin Deficiency
University of Nottingham 75
Not applicableWithdrawnNCT02273349
What this trial is testing

Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency

Who this might be right for
Alpha-1-Antitrypsin DeficiencyChronic Obstructive Lung DiseaseEmphysema
University Hospital, Saarland
Testing effectiveness (Phase 2)WithdrawnNCT05146882
What this trial is testing

An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)

Who this might be right for
Alpha 1-Antitrypsin Deficiency
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation